| Market Cap | 1.01TCr 883.44Cr 814.18Cr 754.65Cr 1.43TCr 96TCr 1.46TCr 9.76TCr 3.8TCr 47TCr 3.79TCr 3.71TCr 1,63400Cr | P/E 2026 * |
179x | P/E 2027 * | 39x |
|---|---|---|---|---|---|
| Enterprise Value | 988.2Cr 864.77Cr 796.97Cr 738.7Cr 1.4TCr 94TCr 1.42TCr 9.56TCr 3.72TCr 46TCr 3.71TCr 3.63TCr 1,60000Cr | EV / Sales 2026 * |
9.82x | EV / Sales 2027 * | 6.87x |
| Free-Float |
65.96% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Corcept Therapeutics
| 1 day | +0.16% |
| Manager | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
CEO | Chief Executive Officer | 68 | 01/01/1999 |
Atabak Mokari
DFI | Director of Finance/CFO | 49 | 01/03/2021 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
BRD | Director/Board Member | 68 | 01/01/1999 |
Gregg Alton
BRD | Director/Board Member | 60 | 12/03/2020 |
George Baker
BRD | Director/Board Member | 83 | 01/01/1999 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.16% | +13.02% | - | - | 1.01TCr | |
| -0.62% | +2.95% | +57.77% | +170.75% | 1,10200Cr | |
| -0.12% | +5.29% | +71.65% | +67.64% | 64TCr | |
| -0.23% | +1.49% | +34.27% | +89.46% | 45TCr | |
| -1.35% | -0.30% | +29.05% | +25.11% | 34TCr | |
| -0.71% | +0.72% | +28.85% | +46.77% | 29TCr | |
| -1.31% | -0.26% | -28.18% | -39.13% | 22TCr | |
| +0.20% | +2.05% | +24.16% | +64.08% | 20TCr | |
| -0.58% | +7.91% | +22.39% | +79.59% | 17TCr | |
| +0.85% | +1.86% | -5.05% | -31.82% | 14TCr | |
| Average | -0.12% | +2.00% | +26.10% | +52.49% | 39.39TCr | |
| Weighted average by Cap. | -0.26% | +1.86% | +40.86% | +86.58% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 100.61Cr 88Cr 81Cr 75Cr 142.77Cr 9.55TCr 145.07Cr 972.93Cr 378.36Cr 4.71TCr 377.71Cr 369.53Cr 16TCr | 140.01Cr 122.53Cr 112.92Cr 104.66Cr 198.68Cr 13TCr 201.88Cr 1.35TCr 526.55Cr 6.56TCr 525.65Cr 514.27Cr 23TCr |
| Net income | 8.57Cr 7.5Cr 6.91Cr 6.41Cr 12Cr 813.63Cr 12Cr 83Cr 32Cr 401.55Cr 32Cr 31Cr 1.39TCr | 37Cr 32Cr 30Cr 28Cr 52Cr 3.5TCr 53Cr 356.42Cr 138.6Cr 1.73TCr 138.37Cr 135.37Cr 5.97TCr |
| Net Debt | -21Cr -19Cr -17Cr -16Cr -30Cr -2.03TCr -31Cr -206.35Cr -80Cr -999.49Cr -80Cr -78Cr -3.45TCr | -47Cr -41Cr -38Cr -35Cr -67Cr -4.5TCr -68Cr -458.57Cr -178.33Cr -2.22TCr -178.03Cr -174.17Cr -7.68TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
